Citations

Citations to this article as recorded by  

• Inhalable iron redox cycling powered nanoreactor for amplified ferroptosis-apoptosis synergetic therapy of lung cancer
  Linjing Wu, Wenhao Wang, Mengqin Guo, Fangqin Fu, Wenhua Wang, Tszching Sung, Meihong Zhang, Ziqiao Zhong, Chuanbin Wu, Xin Pan, Zhengwei Huang
  Nano Research.2024; 17(6): 5435.     CrossRef
• Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
  Akhil Kapoor, Vanita Noronha, Vijay Patil, Nandini Menon, Ravindra Nandhana, Amit Kumar, Abhishek Mahajan, Amit Janu, Rajiv Kumar, Kumar Prabhash
  South Asian Journal of Cancer.2023; 12(02): 179.     CrossRef
• Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis
  Byoung Chul Cho, Dong-Wan Kim, Ullas Batra, Keunchil Park, Sang-We Kim, Cheng-Ta Yang, Pei-Jye Voon, Virote Sriuranpong, K. Govind Babu, Khalid Amin, Yingbo Wang, Paramita Sen, Khemaies Slimane, Sarayut Geater
  Cancer Research and Treatment.2023; 55(1): 83.     CrossRef
• Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
  Xiangming Zhang, Kai Ni, Huijun Chen
  OncoTargets and Therapy.2023; Volume 16: 87.     CrossRef
• A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
  Bei Zheng, Hong Jiang, Wenjuan Yang, Ying Li, Bingqing Liang, Jun Zhu, Nanmei Chen, Miao Chen, Meiling Zhang
  Cancer Medicine.2023; 12(15): 15983.     CrossRef
• Anaplastic Lymphoma Kinase Inhibitor-Induced Neutropenia: A Systematic Review
  Fabien Moinard-Butot, Simon Nannini, Cathie Fischbach, Safa Abdallahoui, Martin Demarchi, Thierry Petit, Laura Bender, Roland Schott
  Cancers.2023; 15(20): 4940.     CrossRef
• Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy
  Ziyu Zhao, Wenhao Wang, Guanlin Wang, Zhengwei Huang, Liping Zhou, Li Lin, Yueling Ou, Wanzhen Huang, Xuejuan Zhang, Chuanbin Wu, Liang Tao, Qin Wang
  Journal of Nanobiotechnology.2023;[Epub]     CrossRef
• Performance of Japanese patients in registrational studies
  Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
  Japanese Journal of Clinical Oncology.2022; 52(1): 53.     CrossRef
• Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
  Laird B Cameron, Nadia Hitchen, Elias Chandran, Tessa Morris, Renée Manser, Benjamin J Solomon, Vanessa Jordan
  Cochrane Database of Systematic Reviews.2022;[Epub]     CrossRef
• Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma
  Kai Chen, Yingnan Si, Jia-Shiung Guan, Zhuoxin Zhou, Seulhee Kim, Taehyun Kim, Liang Shan, Christopher D. Willey, Lufang Zhou, Xiaoguang Liu
  Biomedicines.2022; 10(1): 130.     CrossRef
• The application of radiomics in predicting gene mutations in cancer
  Yana Qi, Tingting Zhao, Mingyong Han
  European Radiology.2022; 32(6): 4014.     CrossRef
• Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review
  Alexis Cortot, Xiuning Le, Egbert Smit, Santiago Viteri, Terufumi Kato, Hiroshi Sakai, Keunchil Park, D. Ross Camidge, Karin Berghoff, Soetkin Vlassak, Paul K. Paik
  Clinical Lung Cancer.2022; 23(3): 195.     CrossRef
• Role ofSTK11inALK‑positive non‑small cell lung cancer (Review)
  Wen Zhou, Lu-Da Yan, Zhi-Qiong Yu, Na Li, Yong-Hua Yang, Meng Wang, Yuan-Yuan Chen, Meng-Xia Mao, Xiao-Chun Peng, Jun Cai
  Oncology Letters.2022;[Epub]     CrossRef
• Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK–Inhibitor-Naive ALK+ Non–Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
  Myung J. Ahn, Hye R. Kim, James C.H. Yang, Ji-Yu Han, Jacky Yu-Chung. Li, Maximilian J. Hochmair, Gee-Chen Chang, Angelo Delmonte, Ki H. Lee, Rosario G. Campelo, Cesare Gridelli, Alexander I. Spira, Raffaele Califano, Frank Griesinger, Sharmistha Ghosh, E
  Clinical Lung Cancer.2022; 23(8): 720.     CrossRef
• Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
  Dan Han, Kewei Zhao, Qin Yang, Liling Zhang, Shihong Fei
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)
  Mei-ting Chen, Xiao-hong Fu, He Huang, Zhao Wang, Xiao-jie Fang, Yu-Yi Yao, Quan-Guang Ren, Ze-geng Chen, Tong-yu Lin
  Leukemia & Lymphoma.2021; 62(3): 571.     CrossRef
• Breakthrough in targeted therapy for non-small cell lung cancer
  Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
  Biomedicine & Pharmacotherapy.2021; 133: 111079.     CrossRef
• Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
  Daniel S.W. Tan, Sarayut Geater, Chong-Jen Yu, Chun-Ming Tsai, Te-Chun Hsia, Jun Chen, Meng-Chih Lin, You Lu, Virote Sriuranpong, Cheng-Ta Yang, Paramita Sen, Fabrice Branle, Michael Shi, Yi-Long Wu
  JTO Clinical and Research Reports.2021; 2(3): 100131.     CrossRef
• Guidelines for clinical practice of ALK fusion detection in non-small-cell lung cancer: a proposal from the Chinese RATICAL study group
  Wenbin Li, Jing Zhang, Zhijie Wang, Lin Li, Jie Ma, Xiaoyang Zhou, Jie Wang, Zhiyong Liang, Jianming Ying
  Journal of the National Cancer Center.2021; 1(4): 123.     CrossRef
• Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study
  Fenge Jiang, Congcong Wang, Ping Yang, Ping Sun, Jiannan Liu
  World Journal of Surgical Oncology.2021;[Epub]     CrossRef
• Genetic Analysis of Pediatric Pancreatoblastoma
  Zhengzheng Wang, Xiaoting Li, Qingjun Li, Jinxue Zhou
  Pancreas.2021; 50(10): 1445.     CrossRef
• Treatment of advanced non-small-cell lung cancer
  Kumar Prabhash, Amish Vora, Sewanti Limaye, Tarini Prasad Sahoo, Ullas Batra, Shekhar Patil, Vijay M. Patil, Vanita Noronha, Bharat Bhosale, Nirmal Vivek Raut, Narayanankutty Warrier, Bharat Vaswani, Govind Babu, Adwaita Gore, Nitesh Rohatgi, Shailesh Bon
  Cancer Research, Statistics, and Treatment.2021; 4(2): 279.     CrossRef
• Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
  Yunpeng Yang, Jianya Zhou, Jianying Zhou, Jifeng Feng, Wu Zhuang, Jianhua Chen, Jun Zhao, Wei Zhong, Yanqiu Zhao, Yiping Zhang, Yong Song, Yi Hu, Zhuang Yu, Youling Gong, Yuan Chen, Feng Ye, Shucai Zhang, Lejie Cao, Yun Fan, Gang Wu, Yubiao Guo, Chengzhi
  The Lancet Respiratory Medicine.2020; 8(1): 45.     CrossRef
• Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
  Lan Song, Zhenchen Zhu, Li Mao, Xiuli Li, Wei Han, Huayang Du, Huanwen Wu, Wei Song, Zhengyu Jin
  Frontiers in Oncology.2020;[Epub]     CrossRef
• Renal complication of crizotinib: Crizotinib-associated complex renal cyst
  Warissara Jutidamrongphan, Pimporn Puttawibul
  The ASEAN Journal of Radiology.2020; : 44.     CrossRef
• A Unique Case of a High-Grade Neuroepithelial Tumor With EML4-ALK Fusion in a Five-Month-Old
  Oliver D Mrowczynski, Russell Payne, Cunfeng Pu, Robert Greiner, Elias Rizk
  Cureus.2020;[Epub]     CrossRef
• Histomorphologic features of lung adenocarcinomas exhibiting ALK gene rearrangement
  Daniel S. Grosser, Haiying Zhang
  Baylor University Medical Center Proceedings.2019; 32(2): 206.     CrossRef
• ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib
  Ye Qiu, Bixun Li, Yihong Zhang, Xiaoyun Guo, Chunzhi Xiang, Congshui Wang, Yang Lu, Shuang Ren, Juan Zhao
  Medicine.2019; 98(11): e14826.     CrossRef
• Emerging therapies for non-small cell lung cancer
  Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
  Journal of Hematology & Oncology.2019;[Epub]     CrossRef
• De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
  Jing-Wen Li, Shu-Hui Cao, Jian-Lin Xu, Hua Zhong
  Cancer Biology & Therapy.2019; 20(9): 1183.     CrossRef
• Incidence and risk of fatigue in cancer patients treated with MET inhibitors
  Hongxuan Tong, Yutian Zhu, Yihua Liu
  Medicine.2019; 98(22): e15522.     CrossRef
• Metastasis manners and the underlying mechanisms of ALK and ROS1 rearrangement lung cancer and current possible therapeutic strategies
  Xing Chang, Zi Liu, Shuai Man, Annie Roys, Zengqiang Li, Daiying Zuo, Yingliang Wu
  RSC Advances.2019; 9(31): 17921.     CrossRef
• Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control
  Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
  Thoracic Cancer.2019; 10(12): 2274.     CrossRef
• Erastin/sorafenib induces cisplatin‑resistant non‑small cell lung cancer cell ferroptosis through inhibition of the Nrf2/xCT pathway
  Yu Li, Hengyi Yan, Xiaoman Xu, Hongbo Liu, Cen Wu, Li Zhao
  Oncology Letters.2019;[Epub]     CrossRef
• Silencing of LncRNA-HOTAIR decreases drug resistance of Non-Small Cell Lung Cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1
  Yan Yang, Caiyu Jiang, Yang Yang, Lu Guo, Jiang Huang, Xingren Liu, Chi Wu, Jun Zou
  Biochemical and Biophysical Research Communications.2018; 497(4): 1003.     CrossRef
• Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices
  Claudio Martín, Andrés F. Cardona, Zyanya Lucia Zatarain-Barrón, Alejandro Ruiz-Patiño, Omar Castillo, George Oblitas, Luis Corrales, Lorena Lupinacci, María Angelina Pérez, Leonardo Rojas, Lisde González, Luis Chirinos, Carlos Ortíz, Mauricio Lema, Carlo
  Oncology.2018; 94(5): 297.     CrossRef
• CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
  Stella Baliou, Maria Adamaki, Anthony Kyriakopoulos, Demetrios Spandidos, Michalis Panagiotidis, Ioannis Christodoulou, Vassilis Zoumpourlis
  International Journal of Oncology.2018;[Epub]     CrossRef